2026 BD opportunity scan for Hangzhou Shangjian Biotechnology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outr

2026 BD opportunity scan for Hangzhou QIANYUAN Pollen Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals a

2026 BD opportunity scan for Hangzhou Highlightll Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and o

2026 BD opportunity scan for Hangzhou Chengbang Pharmaceutical Technology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial sign

2026 BD opportunity scan for Hangzhou Bangshun Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outr

2026 BD opportunity scan for Hangzhou Atom Therapeutics Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach r

2026 BD opportunity scan for Halia Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Hainan Dermavon Pharmaceutical Technology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals

2026 BD opportunity scan for Haihe Biopharma Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Hackensack Meridian Health, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach ratio

2026 BD opportunity scan for Gubra A/S: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Guangzhou Yipinhong Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and ou